Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2012
Assuntos:
Regulatory Issues: FDA
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/
https://ncbi.nlm.nih.gov/pubmed/22643537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares